(VIANEWS) – SALMONES CAMANCHAC (SACAM.OL), FLOW TRADERS (FLOW.AS), GJENSIDIGE FORSIKR (GJF.OL) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. SALMONES CAMANCHAC (SACAM.OL)
296.23% Payout Ratio
Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. The company was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Compañía Pesquera Camanchaca S.A.
Earnings Per Share
As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-2.3.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.94%.
More news about SALMONES CAMANCHAC.
2. FLOW TRADERS (FLOW.AS)
135.8% Payout Ratio
Flow Traders Ltd. operates as a financial technology-enabled multi-asset class liquidity provider in Europe, the Americas, and Asia. The company provides liquidity support that allows investors to continue to buy or sell exchange traded products or other financial instruments. It offers liquidity through financial products. Flow Traders Ltd. was founded in 2004 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, FLOW TRADERS has a trailing twelve months EPS of €0.81.
PE Ratio
FLOW TRADERS has a trailing twelve months price to earnings ratio of 24.26. Meaning, the purchaser of the share is investing €24.26 for every euro of annual earnings.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.3%, now sitting on 596.2M for the twelve trailing months.
More news about FLOW TRADERS.
3. GJENSIDIGE FORSIKR (GJF.OL)
117.61% Payout Ratio
Gjensidige Forsikring ASA engages in the provision of general insurance and pension products in Norway, Sweden, Denmark, Latvia, Lithuania, and Estonia. The company operates through five segments: General Insurance Private, General Insurance Commercial, General Insurance Sweden, General Insurance Baltics, and Pension. It offers motor, property, accident and health, liability, marine/transport, natural perils, agriculture, travel, leisure craft, valuables, commercial, and life insurance products. The company also provides defined contribution occupational pension schemes for businesses, which include disability pension, spouse/cohabitant pension, and child's pension products. It distributes its products through various distribution channels comprising office channel, call center, Internet, partners, and brokers to private and commercial customers. The company was founded in 1816 and is headquartered in Oslo, Norway. Gjensidige Forsikring ASA operates as a subsidiary of GjensidigeStiftelsen.
Earnings Per Share
As for profitability, GJENSIDIGE FORSIKR has a trailing twelve months EPS of kr7.44.
PE Ratio
GJENSIDIGE FORSIKR has a trailing twelve months price to earnings ratio of 24.77. Meaning, the purchaser of the share is investing kr24.77 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.56%.
More news about GJENSIDIGE FORSIKR.
4. UCB (UCB.BR)
75.57% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.76.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 72.81. Meaning, the purchaser of the share is investing €72.81 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Sales Growth
UCB’s sales growth for the current quarter is 6.9%.
Moving Average
UCB’s value is higher than its 50-day moving average of €118.68 and way above its 200-day moving average of €90.87.
More news about UCB.
5. GIMV (GIMB.BR)
40.56% Payout Ratio
Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer 2020; Connected Consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer 2020, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. It mainly focuses on European market and midcap companies in Flanders and Brussels, and also invests in Kazakhstan, Benelux, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. Within consumer 2020, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. It invests in small and medium sized businesses primarily with headquarters in the Benelux, France, and Germany with an enterprise value of up to €125 million ($144.76 million). Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies with headquarters in Benelux, France and DACH region. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced computation power, and components and systems for efficient use of energy, in terms of production, storage, management, use and transport sectors. It focuses on B2B products and services, based on innovation, advanced engineering, advanced manufacturing or software. It also makes flexible equity investment (equity, semi-equity, minority or majority) but always with a meaningful impact on the company and an exit trigger. Within sustainable cities, it focuses on Products, services and infrastructure for building sustainable urban societies: Utilities and consumer goods related to energy and other (raw) materials, Waste treatment, recycling and recovery, Construction and Infrastructure, Transport and Logistics Services, and biomass, green (sustainable) chemistry, water, offshore and maritime solutions and energy efficient infrastructure. It invests through (mezzanine, equity, minority or majority) but will always strive to have a meaningful impact on the company strategy and need an exit trigger. It also invests in semiconductors, chemicals, agriculture, clean technology, electronics, water processing and purification technologies. It seeks to invest in small to medium companies with headquarters in the Benelux, France and Germany (DACH) targeting an international customer base. For fund of fund investments, it seeks to invest in Europe. It seeks to invest between €2.5 million ($2.90 million) to €300 million ($425.44 million) with an enterprise value between $86.85 million and $868.55 million and sales value ranging from €5 million ($6.67 million) million to €400 million ($567.25 million). It typically makes investments between €3 million ($3.47 million) to €10 million ($11.58 million) in the biopharma and MedTech and between €10 million ($11.58 million) to €30 million ($34.74 million) in the health and care services. It may take a majority or a minority stake in its portfolio companies. Its investment horizon is between four and seven years. It also seeks a board seat in its portfolio companies. It invests with capital from its own balance sheet and through various funds under management. Gimv NV was founded on February 25, 1980 and is based in Antwerp, Belgium with additional offices in Paris, France; Hague, The Netherlands; Frankfurt am Main, Germany; London, United Kingdom; Prague, Czech Republic; Warsaw, Poland; and Munich, Germany.
Earnings Per Share
As for profitability, GIMV has a trailing twelve months EPS of €7.85.
PE Ratio
GIMV has a trailing twelve months price to earnings ratio of 5.89. Meaning, the purchaser of the share is investing €5.89 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.99%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 3, 2023, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 5.83%.
Volume
Today’s last reported volume for GIMV is 4227 which is 72.26% below its average volume of 15239.
Yearly Top and Bottom Value
GIMV’s stock is valued at €46.20 at 22:10 EST, under its 52-week high of €47.65 and way higher than its 52-week low of €36.15.
More news about GIMV.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.
Sales Growth
1’s sales growth is 1% for the current quarter and 1% for the next.
More news about 1.
